Press releases

Galenica reports strong sales growth once again

Ad hoc announcement pursuant to Art. 53 LR, Thursday, 23 January 2025

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).

Galenica increases sales growth in the third quarter

Ad hoc announcement pursuant to Art. 53 LR, Thursday, 24 October 2024

Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.8 million to the end of September 2024. With growth of 4.1%, Galenica outperformed the growth of the overall pharmaceutical market (+2.9%, IQVIA, pharmaceutical market Switzerland, YTD September 2024). 

Galenica achieves solid growth in a challenging market environment

Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 6 August 2024

Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024. Both the “Products & Care” segment and the “Logistics & IT” segment contributed to the sales growth, with growth of 3.1% and 3.0% respectively. As a result, Galenica Group sales developed more dynamically than the market.

Subscribe to press releases

Galenica Ltd.
Media
Untermattweg 8
3027 Bern

Footer